Mark R. Olsen

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

Jyoti D. Patel, Mark A. Socinski, Edward B. Garon et al. · Journal of Clinical Oncology · 2013 · 374 citations · Full text

Medicine, Oncology, Pharmacology +13

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, Mark R. Olsen et al. · Journal of Clinical Oncology · 2012 · 275 citations · Full text

Medicine, Oncology, Pharmacology +17

Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study

Nicholas J. Vogelzang, Mark R. Olsen, Joshua J. McFarlane et al. · Clinical Genitourinary Cancer · 2020 · 106 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial

H. Ian Robins, Anne O’Neill, Mark R. Gilbert et al. · Cancer Chemotherapy and Pharmacology · 2007 · 55 citations

Medicine, Oncology, Pharmacology +16

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920

Hamid Emamekhoo, Mark R. Olsen, Bradley Curtis Carthon et al. · Cancer · 2021 · 51 citations · Full text

Medicine, Oncology, Pharmacology +11